Hypertension and current issues in compliance and patient outcomes

被引：63

作者：

Zyczynski T.M. ^{[1
]}

Coyne K.S. ^{[2
]}

机构：

[1] AstraZeneca, LP, Health Economics and Outcomes Research, Wayne, PA 19087-5677

[2] MEDTAP International, Inc., Bethesda, MD 20814

来源：

Current Hypertension Reports | 2000年 / 2卷 / 6期

关键词：

Losartan; Amlodipine; Antihypertensive Therapy; Telmisartan; Cilazapril;

D O I：

10.1007/s11906-996-0034-7

中图分类号：

学科分类号：

摘要：

Economic and human costs associated with untreated or inadequately controlled hypertension and its complications continue to be an issue in the United States despite the availability of numerous antihypertensive agents. Knowledge of hypertension, product profiles, tolerability concerns, convenience of dosing, health-related quality of life effects, and cost of therapy are some of the factors that may influence the compliance of patients to their medication regimens. Recent reports on patient noncompliance have focused on patient-provider relationships, psychosocial barriers, home blood pressure monitoring, and electronic monitoring systems to improve blood pressure control. The use of health-related quality of life assessment in antihypertensive studies and in routine clinical practice provides another opportunity to optimize a patient's regimen for short- and long-term hypertension control in a cost-effective manner. Copyright © 2000 by Current Science Inc.

引用

页码：510 / 514

页数：4

共 29 条

[1]

Burt V.L., Cutler J.A., Higgins M., Et al., Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the Health Examination Surveys, 1960 to 1991, Hypertension, 26, pp. 60-69, (1995)

[2]

(2000)

[3]

Ebrahim S., Detection, adherence and control of hypertension for the prevention of stroke: A systematic review, Health Technol Assessment, 2, pp. 20-28, (1998)

[4]

Dusing R., Weisser B., Mengden T., Et al., Changes in antihypertensive therapy - The role of adverse effects and adherence, Blood Press, 7, pp. 313-315, (1998)

[5]

Kjellgren K.I., Svesson S., Ahlner J., Et al., Antihypertensive medication in clinical encounters, Int J Cardiol, 64, pp. 161-169, (1998)

[6]

Hill M.N., Bone L.R., Kim M.T., Et al., Barriers to hypertension care and control in young urban black men, Am J Hypertens, 12, pp. 951-958, (1999)

[7]

Vaur L., Vaisse B., Genes N., Et al., Use of electronic pill boxes to assess risk of poor treatment adherence, Am J Hypertens, 12, pp. 374-380, (1999)

[8]

Andrejak M., Genes N., Vaur L., Et al., Electronic pill-boxes in the evaluation of antihypertensive treatment adherence: Comparison of once daily versus twice daily regimen, Am J Hypertens, 13, pp. 184-190, (2000)

[9]

Mounier-Vehier C., Bernaud C., Carre A., Et al., Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release, Am J Hypertens, 11, pp. 478-486, (1998)

[10]

Waeber B., Burnier M., Brunner H.R., Compliance with antihypertensive therapy, Clin Exp Hypertens, 21, pp. 973-985, (1999)

← 1 2 3 →